Equities

Prenetics Global Ltd

PRE:NMQ

Prenetics Global Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.36
  • Today's Change-0.165 / -3.65%
  • Shares traded10.04k
  • 1 Year change-40.19%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5716445
Total Receivables, Net216247
Total Inventory3.134.536.83
Prepaid expenses3.30----
Other current assets, total9.20117.41
Total current assets94242107
Property, plant & equipment, net5.781313
Goodwill, net29343.98
Intangibles, net131524
Long term investments108----
Note receivable - long term--0.79--
Other long term assets0.741.290.69
Total assets254312149
LIABILITIES
Accounts payable1.677.299.98
Accrued expenses6.049.7526
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.502.881.67
Other current liabilities, total303721
Total current liabilities395759
Total long term debt0.873.76490
Total debt2.376.65492
Deferred income tax2.613.190.66
Minority interest3.806.40(0.08)
Other liabilities, total1.054.52--
Total liabilities4875549
SHAREHOLDERS EQUITY
Common stock0.020.010.00
Additional paid-in capital------
Retained earnings (accumulated deficit)206237(401)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity206237(401)
Total liabilities & shareholders' equity254312149
Total common shares outstanding129.137.40
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.